IMJUDO 20 mg/ml concentrate for solution for infusion. clinical trials
5 indexed studies · 0 currently recruiting
- Ongoing, recruitingPhase I and Phase II (Integrated)- Other
ABIMMUNE: A Phase I/II study evaluating the safety and clinical activity of anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) antibodies administrated in combination with stereotactic body radiotherapy (SBRT) in patients with metastatic squamous cell carcinoma of head and neck, lung, oesophageus, cervix, vagina, vulva or anus.
This study looks at combining new cancer drugs with a special type of radiation for specific cancers that have spread. We want to see if this treatment is safe and if it helps shrink tumours. It's for certain cancers in the head, neck, lung, food pipe, and female private parts.
For: Metastatic squamous cell carcinoma of head and neck · lung · esophagusFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
Phase 2 Study of Preoperative Gemcitabine Plus Cisplatin with Durvalumab (MEDI4736) and Tremelimumab in intrahepatic cholangiocarcinoma (NeoTreme)
This study is testing a new combination of medicines before surgery for a rare type of liver cancer called intrahepatic cholangiocarcinoma. It aims to see if these medicines can help more patients have successful surgery by making the tumour smaller or easier to remove.
For: intrahepatic cholangiocarcinomaGermany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study of Tremelimumab (Day 1 only), Durvalumab (MEDI4736) and Trans-arterial catheter chemoembolization (TACE)in patients with advanced Hepatocellular Carcinoma (HCC)
This study is looking at a new combination of medicines and a treatment called TACE for people with advanced liver cancer. It aims to see if this combination can stop the cancer from growing for at least 6 months and if it's safe.
For: Advanced Hepatocellular Carcinoma (HCC)Ireland - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Cancer
This study looks at new treatments for advanced bladder cancer that can’t be removed by surgery. It compares two new medicines, alone or together, against standard chemotherapy to see which helps people live longer and stops cancer from growing.
For: ureters · urinary bladder · and urethra)Spain · Greece - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
Durvalumab (MEDI4736 ) plus tremelimumab in resectable, locally advanced squamous cell carcinoma of the oral cavity: a window of opportunity study
This study looks at new drug combinations before surgery for a type of mouth cancer. Researchers want to see if these drugs can boost the body's immune response inside the cancer. It's an early-stage study to understand if these treatments could be helpful and safe for patients.
For: Resectable · locally advanced squamous cell carcinoma of the oral cavity.Belgium